Browse our archive of publications written by CELT scientists below.

Click here to find our most popular articles, recognised by leading academic journals.


Our publications

You can refine your search results by using the keyword search function.

Publication date

Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants


  Hentzien, M., Owen, A., Strub-Wourgaft, N., Perez-Casas, C., Troseid, M., & Calmy, A  Frotiers in Microbiology 

The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases

  Flexner, C., Siccardi, M., Bunglawala, F., & Owen, A.  Clinical Infectious Diseases 
2022-11-21 Prospects for Long-Acting Treatments for Hepatitis C   Thomas, D. L., Owen, A., & Kiser, J. J.  Clinical Infectious Diseases  
2022-11-21 Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment   Ammerman, N. C., Nuermberger, E. L., Owen, A., Rannard, S. P., Meyers, C. F., & Swindells, S.  Clinical Infectious Diseases 

A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm

  Neary, M., Owen, A., & Olagunju, A.  Clinical Infectious Diseases 

Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial

  Chandiwana, N., Kruger, C., Johnstone, H., Chughlay, M. F., Ju, C., Kim, B., . . . Venter, W. D. F. eBio Medicine 

FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

fxr inhibitor, sars-cov-2, ace2  Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., Sampaziotis, F.  Nature 

WHO Living Guidelines on antivirals for COVID-19 are evidence-based

antiviral, covid  Owen, A., Diaz, J. V., Guyatt, G., Lamontagne, F., Stegemann, M., Vandvik, P. O., & Agoritsas, T.   The Lancet 

Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study

covid, favipiravir  Sirijatuphat, R., Manosuthi, W., Niyomnaitham, S., Owen, A., Copeland, K. K., Charoenpong, L., Chokephaibulkit, K  Emerging Microbes and Infections 

Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants 

  Neill Liptrott, Tom McDonald, Andrew Owen, Steve Rannard, et al. Journal of Materials Chemistry B

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection

  Simiso Sokhela; Bronwyn Bosch; Andrew Hill; Bryony Simmons; Joana Woods; Hilary Johnstone; Godspower Akpomiemie; Leah Ellis; Andrew Owen; Carmen Perez Casas et al.  Journal of Antimicrobial Chemotherapy 

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

  Frauke Assmus; Jean-Sélim Driouich; rana abdelnabi; Laura Vangeel; Franck Touret; Ayorinde Adehin; Palang Chotsiri; Maxime Cochin; Caroline S. Foo; DIRK JOCHMANS, Andrew Owen, et al Microorganisms 

Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse

  Frauke Seehusen; Jordan J. Clark; Parul Sharma; Eleanor G. Bentley; Adam Kirby; Krishanthi Subramaniam; Sabina Wunderlin-Giuliani; Grant Hughes; Edward Patterson; Benedict Michael, Andrew Owen et al.  Viruses 

Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells


Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Suelen S. G. Dias, Jairo R. Temerozo, Aline de Paula D. Da Silva, Carine S. da Silva, Camilla Blanco, André C. Ferreira, Mayara Mattos, Vinicius C. Soares, Filipe Pereira-Dutra, Milene Dias Miranda, Debora F. Barreto-Vieira, Marcos Alexandre N. da Silva, Suzana S. Santos, Mateo Torres, Otávio Augusto Chaves, Rajith K. R. Rajoli, Alberto Paccanaro, Andrew Owen, Dumith Chequer Bou-Habib, Patrícia T. Bozza, Thiago Moreno L. Souza



Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry

LC-MS/MS, Cervicovaginal fluid, Swab, Pharmacokinetics, Efavirenz

Wellcome Open Research 

Evaluating the impact of systematic hydrophobic modification of model drugs on the control, stability and loading of lipid-based nanoparticles



Journal of Materials Chemistry B 

Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19

COVID-19, SARS-CoV-2, Inflammasome, Complement, Nanomedicine, Endothelium

Danielle Brain, Alex Plant-Hately, Bethany Heaton, Usman Arshad, 
Christopher David, Christian Hedrich, Andrew Owen, Neill J. Liptrott

Advanced Drug Delivery Review

Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments.

Hepatitis C Long-Acting Treatments Patient Preferences Medication Acceptability Novel Drug Delivery Methods.

Weld ED, Astemborski J, Kirk GD, Sulkowski MS, Stephanie K, 
Rothman R, Solomon SS, Matthews GV, Hsieh YH, Verma M,
Traverso G, Swindells S, Owen A, Feld J, Flexner C, Mehta SH, Thomas DL.

Clinical Injectious Diseases

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

nitazoxanide, antiviral, sars-cov-2

L. WalkerR. FitzGeraldG. SaundersR. LyonM. FisherK. MartinI. EberhartC. Woods,
S. EwingsC. HaleR.RajoliL. ElseS. DillyPenchalaA. Amara, D. G LallooM. Jacobs
H. PertinezP. HatchardR. WaughM. LawrenceL. JohnsonK. FinesH. ReynoldsT, 
R. CrookK. ByrneP. MozgunovT. Jaki, S. KhooA. OwenG. GriffithsT. Fletcher

2021-03-20 Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection niclosamide, intramuscular

J. Hobson, A. Savage, A. Dwyer, C. Unsworth, J. Massam, U.
Arshad, H. Pertinez, H. Box, L. Tatham, R. Rajoli, M. Neary,
J. Sharp, A. Valentijn, C. David, P. Curley, N. Liptrott, T. McDonald,
A. Owen, S. Rannard 

2020-11-20 Chasing COVID-19 chemotherapeutics without putting the cart before the horse COVID-19, chemotherapeutics Steve Rannard, Tom McDonald &  Andrew Owen British Journal of Clinical Pharmacology
2020-11-06 Long-acting drugs and formulations for the treatment and prevention of HIV infection. HIV, prevention Flexner C, Owen A, Siccardi M, Swindells S. International journal of Antimicrobial Agents
2020-07-22 Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.  pharmacokinetics, tenofovir, alfenamide, subcutaneous, implant Rajoli RKR, Demkovich ZR, Flexner C, Owen A, Siccardi M. Antimicrobial Agents and Chemotherapy
2020-06-16 Pharmacokinetics of HIV therapies in pregnant patients: an update.  pharmacokinetics, HIV, pregnant Neary M, Owen A, Olagunju A. Expert opinion on Drug Metabolism & Toxicology
2019-10-12 Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations† anhydrous, nanoprecipitation, nanodispersions, tenofovir, disoproxil, fumurate, oil

J. Hobson, P. Curley, A. Savage, A. Al-khouja, M. Siccardi,
C. Flexner, C. Freel Meyers, A. Owen, S. Rannard

Nanoscale Advances
2019-09-13 Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.  microneedle, array, patch, antiretroviral, PBPK

Rajoli RKR, Flexner C, Chiong J, Owen A, Donnelly RF,
Larrañeta E, Siccardi M.

European Journal of Pharmaceutics and Biopharmaceutics
2019-07-29 Long-Acting Injectable Statins-Is It Time for a Paradigm Shift?  statins Tatham LM, Liptrott NJ, Rannard SP, Owen A. Molecules
2019-05-05 Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling.  drug-drug, rifampicin, cabotegravir, rilpivirinet, pharmacokinetic, modeling, pharmacokinetics

Rajoli RKR, Curley P, Chiong J, Back D, Flexner C,
Owen A, Siccardi M.

The Journal of Infectious Diseases
2019-05-01 Towards a Maraviroc long-acting injectable nanoformulation maraviroc

Lee M.Tathama, Alison C. Savage, Andrew Dwyer,
Marco Siccardi, Trevor Scott, Manoli Vourvahis, Andrew Clarke,
Steve Rannard, Andrew Owen

European Journal of Pharmaceutics and Biopharmaceutics
2019-03-29 Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies semi-solid, prodrug, nanoparticles, water-soluble, antiretroviral, HIV

James J. Hobson, Amer Al-khouja, Paul Curley,
David Meyers, Charles Flexner, Marco Siccardi, Andrew Owen,
Caren Freel Meyers & Steve Rannard

Nature Communications
2018-08-01 Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.  tuberculosis, PBPK, proof of concept

Rajoli RKR, Podany AT, Moss DM, Swindells S, Flexner C,
Owen A, Siccardi M.

The International Journal of Tuberculosis and Lung Disease
2018-06-16 The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation.  pharmacokinetic, modeling, solid drug, nanoparticle Siccardi M, Rannard S, Owen A. Advanced Drug Delivery Reviews
2018-03-15 Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems.  efavirenz, solid drug, nanoparticle, haematological Liptrott NJ, Giardiello M, McDonald TO, Rannard SP, Owen A. Journal of Nanobiotechnology
2018-02-09 Modulated Release from Implantable Ocular Silicone Oil Tamponade Drug Reservoirs modulated release, implant, ocular silicone, oil, tamponade

Helen Cauldbeck , Maude Le Hellaye, Tom O. McDonald , Mark Long,
Rachel L. Williams, Steve Rannard , Victoria R. Kearns

Journal of Polymer Science
2018-02-01 Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges.  latent, tuberculosis, TB

Swindells S, Siccardi M, Barrett SE, Olsen DB, Grobler JA, Podany AT,
Nuermberger E, Kim P, Barry CE, Owen A, Hazuda D, Flexner C.

The International Journal of Tuberculosis and Lung Disease
2018-01-22 Long-acting injectable atovaquone nanomedicines for malaria prophylaxis atovaquone, nanomedicines, malaria, prophylaxis

R. Bakshi, L. Tatham, A. Savage, A. Tripathi, G. Mlambo, M. Ippolito,
E. Nenortas, S. Rannard, A. Owen, T. Shapiro

Nature Communications
2017-09-06 Advances in nanomedicine drug delivery applications for HIV therapy.  HIV, drug delivery Curley P, Liptrott NJ, Owen A. Future Science OA
2017-05-24 In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents In silico, dose prediction, rilpivirine, cabotegravir, children, adolescents

Rajith K. R. Rajoli, David J. Back, Steve Rannard, Caren Freel Meyers,
Charles Flexner, Andrew Owen & Marco Siccardi

Clinical Pharmacokinetics
2016-12-28 Controlling drug release from non-aqueous environments: Moderating delivery from ocular silicone oil drug reservoirs to combat proliferative vitreoretinopathy non-aqueous, ocular, silicone, oil, proliferative, vitreoretinopathy

Helen Cauldbeck, Maude Le Hellayea, Mark Long, Stephnie M. Kennedy,
Rachel L. Williams, Victoria R. Kearns, Steve Rannard

Journal of Controlled Release
2016-12-10 Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.  HIV, AIDS, pre-exposure, prophylaxis Nelson AG, Zhang X, Ganapathi U, Szekely Z, Flexner CW, Owen A, Sinko PJ. Official Journal of the Controlled Release Society
2016-08-01 Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy HIV, therapy Andrew Owen, Steve Rannard Advanced Drug Delivery Reviews
2015-06-05 Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.  physiology, Pharmacokinetic, modeling, intramuscular, nanoformulations, HIV Rajoli RK, Back DJ, Rannard S, Freel Meyers CL, Flexner C, Owen A, Siccardi M. Clinical Pharmacokinetics
2014-01-07 New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.  drug delivery, long-acting, injectible Boffito M, Jackson A, Owen A, Becker S. Drugs



Back to: Centre of Excellence for Long-acting Therapeutics